A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

Clinical trial NCT00907205 · COMPLETED

Trial details

NCT number: NCT00907205
Sponsor: Semafore Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced or Metastatic Solid Tumors Cancer Solid Cancers

Start date: 2007-04-01
Primary completion: 2011-01-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.